Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Initiatives
COR logo

Cencora Hits Record Revenue with $7.7 Billion Surge in GLP-1 Sales

COR10-KFiling Date: 11/25/2025
Cencora, Inc.
Description

What this story covers

Cencora's 2025 10-K reveals record revenue growth driven by specialty pharmaceuticals and GLP-1 demand. Despite a $723.9 million impairment and $4.3 billion in litigation liabilities, the company maintains strong cash flows and a shareholder-focused capital allocation strategy.

Story snapshot

CompanyCencora, Inc.
TickerCOR
VariantStandard detailed
Duration18:01
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001140859-25-000131
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in